Sophia Genetics Expands Partnership with Result Laboratorium to Enhance Pharmacogenomics Insights in the Netherlands

Reuters
30 Jun
Sophia Genetics Expands Partnership with Result Laboratorium to Enhance Pharmacogenomics Insights in the Netherlands

SOPHiA GENETICS, a leader in cloud-native healthcare technology, has announced an expanded partnership with Result Laboratorium in the Netherlands to enhance the delivery of pharmacogenomics insights using the SOPHiA DDM™ Platform. This collaboration aims to make pharmacogenomics more accessible across the region by leveraging scalable, decentralized genomics. The SOPHiA DDM™ Platform is GDPR and HIPAA compliant, ensuring high standards of data security and privacy. By acting as a regional hub, Result Laboratorium will enable other institutions to scale pharmacogenomics analysis without needing to develop complex infrastructure, thereby supporting more personalized care through a secure and scalable data ecosystem.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief on June 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10